Rho-kinase (ROCK) has been considered to activate NMII, while ROCK inhibitors, which encourage neurite outgrowth to reestablish neural connections, are effective in treating PD. Conditions resulting from abnormal NMII activity are currently treated using vasodilators, which target myosin to modulate blood pressure. A vasodilator called Fasudil has been successfully used to improve neuron survival and motor function in PD rodent models. Here, MYH14 is linked to Parkinson disease.